These drugs prevent the action of cholinesterases (ChEs), which are responsible for the hydrolysis of the neurotransmitter acetylcholine (ACh), thereby increasing the levels of ACh in the brain and improving the cholinergic functions in AD patients [5,6]. This evidence concerns the gene BCHE and Alzheimer disease.